Mario Brkulj
👨🏻🦳 20+ years in #biopharma #investorrelations & #communications
👱🏼♂️Former journalist, MorphoSys spokesperson, and MacDougall EU practice lead
👉🏻Today: Valency Communications owner
@patchyclamp.bsky.social
Preclinical biologist at small biopharmas following cool ion channel and receptor targets to neuro, renal, and immune indications. Likes electrophysiology (still), fine z-primes, and serial commas. Bostonian by choice (oof). He/him
@carulin.bsky.social
she/her. Immunologist, PhD. Currently rebuilding my science bubble here. Interest in #rheumatology #biopharma #biotech #scicomm #womeninscience 🧪 Views are my own! en/de
@ericnelson1.bsky.social
Biopharma biz dev advisor focused on compound licensing agreements #AI #smallmolecules #geneediting #CNS #licensing 🇩🇪🇨🇭🇨🇳🇸🇪🇰🇷🇫🇷
@gwendolynawu.bsky.social
Covering biotech startups and VCs at BioPharma Dive. Hobbyist baker and dog wrangler.
@pottslab.bsky.social
VP & Head of Induced Proximity Platform, @Amgen | Scientist | Father
@drrichjlaw.bsky.social
Chief Business Officer of Haya Therapeutics! (formerly Exscientia/Recursion CBO), computational chemist by training (Oxford, UCSD, LLNL & Evotec), bike racer, ex-Oxford rower & LFC fan! #YNWA.